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OBJECTIVES: Radiation-induced nausea and vomiting (RINV) is commonly experi-
enced by cancer patients undergoing radiation treatment. Current NCCN guide-
lines recommend the use of the 5-hydroxytryptamine-3 serotonin receptor antag-
onists (5-HT3-RAs) for the prevention and treatment of RINV. The purpose of this
study was to examine the incidence of 5-HT3-RA utilization and subsequent RINV,
in patients diagnosed with colon cancer and undergoing radiation treatment.
METHODS: This was a retrospective analysis using HIPAA-compliant medical and
pharmacy claims in a commercially-insured U.S. patient population. The study
identified continuously enrolled adult patients diagnosed with colon cancer who
received radiation treatment during the period from 4/1/2007 to 8/31/2009. Patients
receiving combination chemotherapy were excluded. The index date was the date
of initiation of radiation treatment and patients were followed for 30 days. Prophy-
lactic administration of a 5-HT3-RA was defined by medication on the day of or the
day prior to radiation therapy. The incidence of RINV was calculated from medical
claims for an outpatient appointment, inpatient admission, or ER visit with a pri-
mary diagnosis of RINV. RESULTS: A total of 2,400 patients were identified as
meeting the inclusion and exclusion criteria for the study. Average age of patients
was 57.6 years old and 43.8% were female. Radiation therapy included localized
treatment (48.6%), total body irradiation (30.9%), or both (20.5%). Of the patients
identified, 73.9% received no 5-HT3-RA, 5.0% were treated prophylactically, and
21.1% received a 5-HT3-RA in the days after radiation therapy. Of the patients who
received the 5-HT3-RA prophylactically, 58.2% were treated with an oral formula-
tion. Incidence of subsequent RINV for all patients, independent of rescue medica-
tion use, was 15.2%. CONCLUSIONS: The results showed use of the 5-HT3-RA an-
tiemetics in patients undergoing radiation treatment for colon cancer was
uncommon and prophylactic administration was relatively rare.
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OBJECTIVES: To determine the number of patients with diagnosed acute myeloid
leukaemia (AML) including chemotherapy rates, types and care settings using sick-
fund data. METHODS: Data provided by 4 statutory sick funds (SHI) and 2 data
providers were analyzed for 2010. AML diagnosis was identified by ICD-10 C92.0
and other types of cancer by ICD-10 C00-79; D00-09; D37-48. Prevalence was extrap-
olated to the German population by correcting for a representative age- and gender
distribution. RESULTS: The median proportion of AML patients  60 years was
61.1% or 6,590 patients (SHI A: 63.0% 4,938; B: 50.9% 5,858; C: 68.9% 8,975). The
proportion of AML patients  65 years (sick fund D) was 47.6% or 4,400 patients.
Gender ratio was 57% male and 43% female. On average, 2 additional oncological
disorders were found in 77% of AML patients. 50% had an unspecified leukaemia
(C95.90), 25% had CML (C92.1*) and 20% MDS (D46.9). Among patients65 years the
rate of treatment was 60.9% (Anatomical Therapeutic Chemical (ATC) Code L01*
(40%), pharmacy number (PZN) 9999092 (19%), operating and procedure code (OPS)
854* (26%)). 16.4% received both out- and inpatient treatment, 34.5% received out-
patient treatment and 10.0% inpatient treatment. Identification of comppunds was
possible when ATC codes were reported. 63.6% received imatinib and/or hydroxy-
carbamide, 11.4% tioguanine, 9.1% mercaptopurine, 9.1% cytarabine and 6.8% re-
ceived dasatinib. The outpatient treatment rate in patients  60 years diagnosed
with AML only was 34.3% (6,2% mercaptopurine and idarubicine, 28.1% PZN
9999092). CONCLUSIONS: Prevalence was higher than previously reported inci-
dence numbers of 3,100 AML patients (SHI, all age groups). The yearly outpatient
treatment rate was relatively low with 34.3% in patients diagnosed with AML alone.
Other oncological disorders are likely to be diagnosed before AML diagnosis could
be confirmed. Treatment rates increased with additional oncological disorders
with the use of substances not approved for AML.
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WITH PANITUMUMAB PLUS FOLFOX VERSUS FOLFOX ALONE
Wang J1, Zhao Z2, Barber B2, Zhang J1, Sherrill B1, Braun S3, Sidhu R2, Gallagher M2,
Douillard JY4
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Amgen Inc., Thousand Oaks, CA, USA,
3Amgen (Europe) GmbH, Zug, Switzerland, 4ICO R. Gauducheau, ST HERBLAIN, France
OBJECTIVES: Panitumumab plus FOLFOX significantly improved progression-free
survival (PFS) in patients with WT KRAS mCRC. The objective of this analysis was to
use the quality-adjusted time without symptoms of disease or toxicity of treatment
(Q-TWiST) method to compare quality-adjusted survival between the treatment
arms. METHODS: Patients with mCRC were randomized to panitumumab plus
FOLFOX or FOLFOX alone in a phase III clinical trial. For each treatment arm, the
area under the survival curve, which was estimated using the Weibull distribution,
was partitioned into health states: toxicity (TOX), time without symptoms of dis-
ease progression or toxicity (TWiST, i.e., PFS minus TOX), and relapse period (REL,
i.e., overall survival (OS) minus PFS); and adjusted using utility weights derived
from patient-reported EuroQoL 5-dimensions measures. The null hypothesis of no
difference between treatment groups was tested based on the normal approxima-
tion with standard errors calculated by the bootstrap method. Sensitivity analyses
were performed using the standard Q-TWiST approach with means restricted to
median OS. RESULTS: Of 1,183 patients who were randomly assigned, 1,096 pa-
tients (93%) had available tumor KRAS status, of which 656 patients (60%) had WT
KRAS tumors (panitumumab plus FOLFOX, n325; FOLFOX alone, n331) and were
included in this analysis. Compared to patients treated with FOLFOX alone, the
panitumumab plus FOLFOX group had significantly longer quality-adjusted PFS
(8.5 versus 7.2 months, respectively; 1.3 additional quality-adjusted months; p 
0.02) and quality-adjusted OS (22.4 versus 18.6 months; 3.8 additional quality-ad-
justed months; p 0.04). When analysis was restricted to 24 months follow-up, the
Q-TWiST advantage was smaller but still significant (14.0 versus 13.0 months; 1.0
additional quality-adjusted month; p  0.04). CONCLUSIONS: This Q-TWiST anal-
ysis showed that in patients with previously untreated WT KRAS mCRC, panitu-
mumab plus FOLFOX significantly improved the duration of the quality-adjusted
survival compared with FOLFOX alone.
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OBJECTIVES: About a decade ago, the introduction of the tyrosine kinase inhibitor
(TKI) imatinib dramatically extended the life span of chronic myeloid leukemia
(CML) patients. Currently, there are several different TKIs approved for CML treat-
ment. The goal of this study is to develop a clinical decision-analytic model for the
evaluation of the comparative long-term effectiveness of first-line therapy for CML
within the Austrian health care context.METHODS:We developed a Markov state-
transition model for patients in the chronic-phase of CML treated with first-line TKI
imatinib, dasatinib or nilotinib. Seven different strategies including different com-
binations of first and second-generation TKIs as well as chemotherapy or stem cell
transplantation were evaluated. The model was parameterized using published
trial data, data from the Austrian CML registry and from an Austrian CML expert
panel. The model was analyzed as a cohort simulation over a lifelong time horizon.
Health outcomes evaluated were life-years (LYs) gained and quality-adjusted life
years (QALYs) gained. Deterministic and structural sensitivity analyses were
performed. RESULTS: Nilotinib followed by dasatinib after failure is the most ef-
fective treatment in terms of both LYs gained (19.71 LY) and QALYs gained (17.08
QALYs). All strategies including a second-line TKI were superior compared to strat-
egies without second-line TKI. Deterministic sensitivity analyses showed that the
ranking of the strategies was mostly influenced by the duration of first- and sec-
ond-line therapies. In a structural sensitivity analysis, where patients move di-
rectly from second-line TKI therapy to advanced stage of disease, strategies with-
out second-line therapy are most effective. CONCLUSIONS: Based on our analyses
results, the most clinically effective strategy is nilotinib followed by dasatinib as
second-line therapy. All three TKIs are approved as first-line therapy in Austria.
Our results may support clinicians and patients in their decision making.
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CABAZITAXEL PLUS CORTICOSTEROIDS IN COMPARISON TO
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OBJECTIVES: A combination Cabazitaxel plus Corticosteroids (CC) has been shown
to prolong survival in patients with mHRPC versus Mitoxantrone plus Corticoste-
roids (MC) in the TROPIC study of patients with mHRPC. As there is no direct
comparison CC vs. Corticosteroids (C) as requested by the German regulatory bod-
ies we aimed to provide an indirect comparison.METHODS:A systematic search of
the DIMDI database was conducted in 12/2011. Data were combined using meta-
analyses and indirect comparisons (“Bucher et al. J Clin Oncol 2008”). The end-
points analysed were all cause mortality overall and in patients with or without
pain and pain response (Hazard/Response Ratios with 95%-confidence intervals).
RESULTS: A total of 168 potential publications resulted in three relevant studies
(Berry, 2002; Kantoff, 1999; Tannock, 1996) for MC vs. C. A meta-analysis of mortal-
ity in the three studies resulted in HR0.92 (95%-CI 0.74-1.13) for MC vs. C. Com-
bined with TROPIC (CC vs. MC 0.70; 0.59-0.83) the indirect comparison (CC vs. C)
resulted in HR0.64 (0.49-0.84). For mortality in patients without pain at baseline,
the HR for MC vs. C was 0.89 (0.59-1.34) (Berry). The indirect comparison CC vs. C
resulted in HR0.51 (0.30-0.84) using TROPIC patients without pain (HR0.57; 0.42-
0.77). For mortality in patients with pain at baseline, the HR for MC vs. C was 0.83
(0.60-1.16) (Tannock). The indirect comparison CC vs. C resulted in HR0.65 (0.43-
0.98) using TROPIC patients with pain (HR0.78; 0.60-1.00). In patients with pain at
baseline, pain response was higher with MC vs. C (RR2.33; 1.19-4.57) (Tannock).
The indirect comparison CC vs. C resulted in RR2.77 (1.05-7.32) using TROPIC
patients with pain (RR1.19; 0.59-2.39). CONCLUSIONS: The analyses indicate a
statistically significant reduction of mortality in patients with mHRPC receiving CC
vs. C with or without pain and an increased pain response.
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OBJECTIVES: Little is known about the use and effectiveness of new treatments for
metastatic renal cell carcinoma (mRCC) in daily practice. In the Netherlands, this
information is needed for expensive inpatient drugs to guarantee continued reim-
bursement. We evaluated the use and effectiveness of bevacizumab plus interferon
alfa-2a (IFN) for patients with mRCC in Dutch daily practice. METHODS: A popula-
tion-based registry was created to include patients newly diagnosed with mRCC
from 2008-2010. These patients represent 55% of all patients in the Netherlands.
Data were collected on patient and disease characteristics, treatments, dosages,
treatment response, survival, adverse events and resource use. RESULTS: To date,
data on 615 patients have been collected. Average age at diagnosis was 66.4 years
(range: 23-93) and 66% was male. 53% of these patients received systemic therapy.
The majority (83%) was treated with sunitinib, whereas sorafenib is most often
used as second-line treatment. Data from 34 patients treated with bevacizumab
plus IFN in the first line were collected. The dosage corresponded with the recom-
mended dosage (10 mg/kg). Since the mean weight of patients in daily practice was
higher than the mean weight seen in the phase III trial (87.5 vs 76.0 kg), the mean
dosage was also higher. Of the 34 patients treated with bevacizumab plus IFN,
median overall survival was similar to that seen in the phase III trial (23.0 vs 23.3
months).CONCLUSIONS: Feasibility issues come into play when evaluating the use
and effectiveness of expensive inpatient drugs in daily practice. Since bevaci-
zumab plus IFN is not regularly used in daily practice, future cost-effectiveness
analyses will have to be based on a careful synthesis of evidence from daily prac-
tice, the phase III trial, quality of life studies and other sources.
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A SYSTEMATIC REVIEW OF THE HETEROGENEITY OF TREATMENT EFFECT IN
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OBJECTIVES: Clinical studies typically assess average treatment effect on out-
comes, potentially ignoring heterogeneity of treatment effect associated with phe-
notypic and genotypic characteristics. A paradigm shift where drugs are targeted to
disease subtypes based on molecular biomarkers, rather than phenotypic or histo-
logical characteristics alone, is underway and beginning to influence outcomes
research. Our objective was to assess heterogeneity of treatment effect associated
with adjuvant and advanced-stage therapy for OC and strength of evidence docu-
menting association between patient or tumor characteristics and outcomes.
METHODS: We conducted a review according to the Cochrane Handbook of Sys-
tematic Reviews, with two independent reviewers completing study selection from
11 databases and data extraction on several outcomes: overall survival (OS), pro-
gression-free survival (PFS), tumor response, disease-free survival, time to progres-
sion, adverse events, and quality of life (QOL). Studies that did not evaluate char-
acteristics identified as predictive of anti-cancer treatment outcome, regardless of
whether treatment was molecularly targeted, were excluded. Descriptive analyses
were conducted. RESULTS: Forty-seven of 554 publications were selected (93%
concordance between reviewers). Most studies presented post-hoc analyses (45/
47); over half evaluated platinum-taxane combinations (27/47). Fifty-three distinct
patient or tumor characteristics were evaluated for association with outcomes.
Nine of the 10 most frequently studied characteristics were molecular: p53, VEGF,
ERCC1, CA-125, CD31-MVD, stathmin, TSP1-1A, III-tubulin and CD24. No studies
assessed predictive factors for QOL. Elevated CA-125 and stathmin levels were each
predictive of worsening OS and PFS, and VEGF levels or genotype were mostly
unrelated to OS or PFS. CONCLUSIONS: There are numerous studies that associate
mostly molecular markers with traditional measures of treatment effect; however,
patient-centered outcomes in this context have not yet been studied in OC. Future
evaluations of treatment effect in OC should also consider variation in these pa-
tient and tumor characteristics, in addition to histological and phenotypic charac-
teristics, for association with QOL.
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OBJECTIVES:To compare overall survival (OS) and progression free survival (PFS) in
sunitinib-refractory (SU-r) patients with mRCC treated with AXI and BSC using STC.
METHODS: STC method was used to derive OS and PFS curves for a hypothetical
cohort of “AXI-like” patients had they received BSC in the AXIS trial. Patient level
data on SU-r patients from the AXIS trial were used to derive predictive equations
for OS and PFS. Parametric survival analysis identified the best fitting distribution
and significant predictors of OS and PFS. These equations were calibrated using
patient characteristics and mPFS and cross-over adjusted mOS of the BSC cohort in
the RECORD-1 trial. RESULTS: In AXIS all 194 SU-r AXI patients progressed on one
line of treatment. In RECORD-1 78% of BSC patients had 2 prior lines and some
failed 1st line treatment due to intolerability. Other available patient characteristics
were comparable except for MSKCC risk category (36% vs 15% poor risk, AXI vs BSC
respectively) and ECOG score (52% vs 68% with ECOG 0). The final predictive equa-
tions using the best-fitting log-normal distribution included MSKCC risk group and
age for PFS, and MSKCC risk category and duration of prior SU for OS. Median
estimated OS and PFS was 15.2 and 5.1 months for AXI compared to 8.3 and 1.6
months for BSC respectively. Estimated difference in mean OS and PFS between
AXI and BSC was 11.4 and 5.9 months. Sensitivity analyses using patient charac-
teristics of the SU-r subgroup of everolimus arm and Weibull distribution showed
similar results. CONCLUSIONS: The STC analysis, an alternative to mixed treat-
ment comparison, suggested a significant improvement in OS and PFS for SU-r
mRCC patients treated with AXI compared to BSC. However, the analysis could not
account for all the differences between patient populations, particularly for the
number of prior non-VEGFR-TKI therapies.
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MODELING LIFETIME EFFECTIVENESS OF DENOSUMAB VERSUS PLACEBO IN
MEN WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC) AT HIGH RISK
OF DEVELOPING BONE METASTASIS (BM)
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OBJECTIVES: With increasing health care resource constraints, it is important to
understand the incremental cost-effectiveness (ICER) of new medicines, and an
integral effort is to predict key clinical and economic outcomes over the patients’
lifetime. Our objective was to predict the lifetime mean overall survival (OS) and
bone metastasis-free survival (BMFS) for denosumab (120mg subcutaneous every 4
weeks) vs. placebo in men with CRPC based on a recent phase III trial (ClinicalTri-
als.gov NCT00286091).METHODS: A three-state health state model (BMFS, BM pro-
gression, and Death) was developed. Parametric survival functions for OS and
BMFS were estimated using trial data and extrapolated for lifetime. Model selection
was based on the best fit within trial duration (AIC criteria), and overall shape of the
lifetime predictions. For the parametric estimation, consistent with trial results,
pooled data from both study arms were used for OS; the placebo arm was used for
the baseline BMFS and the trial reported treatment effect (HR) was applied to derive
the BMFS curve for denosumab. RESULTS: A Weibull function was identified as the
best fit for both OS and BMFS. The pooled mean estimate was 4.02 years for OS, and
2.75 and 3.16 years for BMFS in placebo and denosumab respectively, resulting in
an incremental BMFS of 0.41 year for denosumab vs placebo. CONCLUSIONS: De-
nosumab treatment is predicted to prolong time in BMFS, which will reduce time in
BM progression state with potentially lower costs and costs offsets for denosumab
from reduced need of routine care in the metastatic health state. This finding will
facilitate our understanding of the ICER of denosumab in men with CRPC at high
risk of developing BM.
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OBJECTIVES: Chemotherapy-induced nausea and vomiting (CINV) is a significant
adverse effect of cancer chemotherapy treatment. The 5-hydroxytryptamine-3 re-
ceptor antagonists (5-HT3-RAs), a class of antiemetics, is indicated for the preven-
tion and treatment of CINV. The purpose of this study was to examine the use of
rescue antiemetic administration for CINV in patients diagnosed with cancer and
undergoing single-day chemotherapy. METHODS: A retrospective cohort analysis
using the Ingenix LabRx® database was conducted. Adult patients diagnosed with
lung, breast, or colon cancer, treated with a moderately (MEC) or highly emetogenic
chemotherapy (HEC), and who received a prophylactic 5-HT3-RA from 4/1/08 to
3/31/09, were identified. The outcome of interest was the rate of rescue antiemetic
administration, per cycle of chemotherapy, between 5-HT3-RA treatment cohorts.
Rescue antiemetic utilization was defined by a HCPCS code for administration of an
antiemetic from day 2 to the end of the cycle or for 30 days following single-day
chemotherapy. RESULTS A total of 5,912 patients were identified, 25.7% treated
with a HEC regimen and 74.3% on a MEC regimen.The mean age was 56.1 years and
77.1% were female. Patients were treated with a total of 21,821 cycles of chemo-
therapy. The most common 5-HT3-RA utilized was palonosetron (73% of cycles)
followed by ondansetron (11%), granisetron (10%), and dolasetron (6%). The overall
unadjusted rate of rescue antiemetic administration per cycle was 17.6%, and the
rate differed by 5-HT3-RA utilized. Patients treated with palonosetron were signif-
icantly less likely to require a rescue antiemetic on a per cycle basis (14.1%), com-
pared to patients treated with another 5-HT3-RA (26.6%), p.001. CONCLUSIONS:
The results from this retrospective analysis suggest that rescue antiemetic utiliza-
tion may be significantly reduced in patients undergoing chemotherapy following
use of palonosetron vs. another 5-HT3-RA for the prevention of CINV.
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THE IMPACT OF TREATMENT PERSISTENCE WITH LENALIDOMIDE (LEN) FOR
THE TREATMENT OF MULTIPLE MYELOMA (MM) ON DISEASE CONTROL
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OBJECTIVES: While persistence with drug therapy is essential to achieve optimal
patient benefits, poorly controlled MM results in earlier disease progression, dis-
ease-related complications, deleteriously impacts quality of life, and ultimately
death. This study assesses the relationship between treatment LEN adherence/
persistence and indicators of lack of disease control and disease-related complica-
tions of MM. METHODS: Commercial and Medicare Advantage enrollees initiating
LEN for treatment of MM with pharmacy and medical benefits in the 6 months prior
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